Results 51 to 60 of about 1,950 (155)

Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies [PDF]

Background/Objectives: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved to treat anemia of chronic kidney disease (CKD). The efficacy and safety of roxadustat compared with parenteral erythropoiesis-stimulating agents (
Tadao Akizawa, Vicki Santos, Danilo Fliser, Alina Jiletcovici, Santos, Vicki, Najib Khalife, Fliser, Danilo, Bhandari, Sunil, Jiletcovici, Alina, Sunil Bhandari, Alberto Ortiz, Ortiz Arduán, Alberto, Khalife, Najib, Akizawa, Tadao   +13 more
core   +3 more sources

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis

Renal Failure, 2023
Background This meta-analysis aims to assess the efficacy and safety of roxadustat in treating anemia patients with dialysis-dependent (DD) chronic kidney disease (CKD).Methods We comprehensively searched 5 databases for randomized controlled trials ...
Qiaoqiao Zhou, Mian Mao, Jing Li, Furong Deng   +3 more
doaj   +1 more source

A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Cellular senescence influences cancer progression through irreversible cell‐cycle arrest, immune surveillance, and paracrine signaling mediated by the senescence‐associated secretory phenotype (SASP). SASP comprises inflammatory cytokines, chemokines, growth factors, and matrix‐remodeling enzymes that regulate the tumor ...
Sneha Pallatt, Sibin Nambidi, Antara Banerjee, Surajit Pathak   +3 more
wiley   +1 more source

Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit [PDF]

Int J Mol Sci
Bone remodeling relies on a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes osteoblast differentiation but its effects on osteoclasts remain ...
Li A, Zuo L, Li L, Gan L, Wang M, Liang Y, Li Q, Zhao X.   +7 more
europepmc   +2 more sources

Mechanistic Insights Into Hepatotoxicity‐Induced Liver Cirrhosis and Anemia: Iron Dysregulation, the Hepcidin–Ferroportin Axis, and Emerging Therapeutic Strategies

Organ Medicine, Volume 3, Issue 3, Page 171-185, September 2026.
Patients with alcohol‐associated liver cirrhosis or acetaminophen (APAP) toxicity frequently develop anemia with iron metabolism disturbances. Dysregulation of hepcidin–ferroportin signaling, along with inflammation, oxidative stress, hypoxia, impaired intestinal iron absorption, malnutrition, and gastrointestinal bleeding, contributes to anemia ...
Debabrata Dash, Raj Kumar Koiri
wiley   +1 more source

Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 9, September 2026.
ABSTRACT Purpose Hypoxia‐inducible factor prolyl hydroxylase inhibitors (HIF‐PHIs) are increasingly used to treat renal anemia in patients with chronic kidney disease (CKD). We evaluated the risk of heart failure associated with HIF‐PHIs compared with erythropoiesis‐stimulating agents (ESAs) in routine clinical practice.
Yuki Kunitsu, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, Tomohiro Terada   +4 more
wiley   +1 more source

Beneficial effect of roxadustat on early posttransplant anemia and iron utilization in kidney transplant recipients: a retrospective comparative cohort study [PDF]

, 2022
Background: Although posttransplant anemia (PTA) is a common complication after kidney transplant, it has not been thoroughly evaluated for appropriate treatment.
Ciancio, Gaetano, Tao, Ye, Bai, Yang-Juan, Li, Hui, Tadros, Nicholas N., Li, Ya-Mei, Hu, Shu-Meng, Shi, Yun-Ying   +7 more
core   +1 more source

Anemia of Inflammation in Solid Tumor Patients and Practical Education for Oncologists and Nurses

Thoracic Cancer, Volume 17, Issue 17, September 2026.
Tumor‐ and immune‐derived cytokines including IL‐6, IL‐1β, TNF‐α, TGF‐β, IL‐10, and IFN‐γ drive anemia of inflammation: IL‐6/TNF‐α upregulate hepatic hepcidin to block iron export, while other cytokines suppress erythropoiesis and shorten red cell survival.
Xiaoyan Si, Xiaomin Wei, Xiaoyan Liu, Mei Li, Mengzhao Wang, Li Zhang   +5 more
wiley   +1 more source

Hypoxia‐inducible factor‐1a (HIF1a) as a context‐dependent integrator of metabolic stress in skeletal muscle

The Journal of Physiology, Volume 604, Issue 18, Page 7539-7558, 15 September 2026.
Abstract figure legend Hypoxia‐inducible factor‐1a (HIF1a) integrates physiological and pathological inputs in skeletal muscle, including exercise, circadian timing, cytotoxins and disease. These inputs alter mitochondrial oxidative function, redox state, reactive oxygen species, and local oxygen availability, leading to intermittent or sustained HIF1a
Nicole Welch, Pugazhendhi Kannan, Seshu Vardhan Pothabathula, Annette Bellar, Abhishek A. Chakraborty, Saurabh Mishra, Srinivasan Dasarathy   +6 more
wiley   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, Volume 30, Issue 4, Page 585-593, August 2026.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source